JP2016517401A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517401A5
JP2016517401A5 JP2015562243A JP2015562243A JP2016517401A5 JP 2016517401 A5 JP2016517401 A5 JP 2016517401A5 JP 2015562243 A JP2015562243 A JP 2015562243A JP 2015562243 A JP2015562243 A JP 2015562243A JP 2016517401 A5 JP2016517401 A5 JP 2016517401A5
Authority
JP
Japan
Prior art keywords
seq
antisense oligonucleotide
composition
smad7
colorectal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562243A
Other languages
English (en)
Japanese (ja)
Other versions
JP6502863B2 (ja
JP2016517401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055195 external-priority patent/WO2014140333A1/en
Publication of JP2016517401A publication Critical patent/JP2016517401A/ja
Publication of JP2016517401A5 publication Critical patent/JP2016517401A5/ja
Application granted granted Critical
Publication of JP6502863B2 publication Critical patent/JP6502863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562243A 2013-03-15 2014-03-14 結腸直腸癌を処置する方法 Active JP6502863B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361790488P 2013-03-15 2013-03-15
US61/790,488 2013-03-15
US201361847287P 2013-07-17 2013-07-17
US61/847,287 2013-07-17
PCT/EP2014/055195 WO2014140333A1 (en) 2013-03-15 2014-03-14 Methods of treating colorectal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018199148A Division JP2019026649A (ja) 2013-03-15 2018-10-23 結腸直腸癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2016517401A JP2016517401A (ja) 2016-06-16
JP2016517401A5 true JP2016517401A5 (https=) 2017-04-20
JP6502863B2 JP6502863B2 (ja) 2019-04-17

Family

ID=50390057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015562243A Active JP6502863B2 (ja) 2013-03-15 2014-03-14 結腸直腸癌を処置する方法
JP2018199148A Withdrawn JP2019026649A (ja) 2013-03-15 2018-10-23 結腸直腸癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018199148A Withdrawn JP2019026649A (ja) 2013-03-15 2018-10-23 結腸直腸癌を処置する方法

Country Status (11)

Country Link
EP (1) EP2970419B8 (https=)
JP (2) JP6502863B2 (https=)
KR (1) KR102232623B1 (https=)
CN (1) CN105008394B (https=)
AU (1) AU2014229985B2 (https=)
CA (1) CA2903597C (https=)
ES (1) ES2673209T3 (https=)
MX (1) MX363746B (https=)
NZ (1) NZ711564A (https=)
RU (1) RU2674147C2 (https=)
WO (1) WO2014140333A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗smad7治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
WO2017059225A1 (en) * 2015-09-30 2017-04-06 Celgene Corporation Tlr modulators and methods of use
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
RU2593939C2 (ru) * 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗smad7治療に対する応答性をモニターするための方法

Similar Documents

Publication Publication Date Title
JP2016517401A5 (https=)
JP2017529382A5 (https=)
RU2015140572A (ru) Способы лечения колоректального рака
JP2016516073A5 (https=)
ME02597B (me) Inhibitori histonskih demetilaza
JP2016540738A5 (https=)
FI3166615T3 (fi) Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi
MX392126B (es) Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo
FI3897672T3 (fi) HBV-yhdistelmähoito
US20110166092A1 (en) Dosing methods for treating disease
JP2017503014A5 (https=)
RU2016137289A (ru) Схема применения соединения fgf-18
JP2015504438A5 (https=)
JP2016516773A5 (https=)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
MY165964A (en) Preventive or therapeutic agent for fibrosis
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
CN110404067A (zh) 一种治疗结直肠癌的药物组合物
JP2012518602A5 (ja) 癌の予防または処置に使用されるインヒビター及び方法
WO2011151786A3 (en) Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer
ES2703739T3 (es) Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico
JP2016510738A5 (https=)
IL278311B2 (en) Preparations and methods for the treatment of glioblastoma